Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate

...

A 25-year-old biologist is launching a new company with $3.4 million in seed funding to develop a personalized cell therapy using the gene-editing tool CRISPR.

Quanterix has a new chief executive and president in Everett Cunningham, but analysts at Leerink see Illumina’s former commercial chief facing an uphill battle in his bid to turn the medtech’s fortunes around.

Madrigal paid Pfizer $50 million for the rights to a DGAT2i inhibitor that the biopharma intends to combine with its approved liver disease drug Rezdiffra.

AirNexis Therapeutics is taking flight with $200 million and a clinical-stage asset from a China pharma that aims to treat lung disease.

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the commercialization of a blood cancer cell therapy.

The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz.

Nearly a year after leaving his position as longtime director of the National Human Genome Research Institute, Eric Green, M.D., Ph.D., will now step into the commercial life sciences world as the new chief medical officer of Illumina.